Back to search results

COAG-AF Pilot Study for Atrial Fibrillation

This observational pilot study, called COAG-AF, is looking at how certain substances in your blood, called biomarkers, change in people with atrial fibrillation (AFib). Specifically, researchers want to see if an increase in biomarkers like Asymmetric dimethyl arginine (ADMA), P-selectin, Platelet factor 4, and B-thromboglobulin is linked to how much AFib you experience. They also want to see how these biomarkers are affected by a procedure called catheter ablation, which treats AFib. You could be eligible if you are an adult with persistent or paroxysmal AFib who is having a catheter ablation at Tulane University Medical Center and a cardiac MRI (Magnetic Resonance Imaging) as part of your usual care.

Study design
This is a prospective observational pilot study involving about 20 participants. It is not a randomized trial.
What's involved
You would have blood drawn before, during, and after your catheter ablation procedure, including at Day 0, Day 1, Day 2, Day 30, and Day 90. You will also have a cardiac MRI as part of your standard care.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for three months after their ablation procedure, with blood draws at Day 30 and Day 90.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04947657

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

Recruiting
Not specifiedAges 18+Observational
Tulane University
~20 participants
Updated 2026-03-05 on ClinicalTrials.gov

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measure the change in Asymmetric dimethyl arginine (ADMA) in relation to atrial fibrillation burden
Measured over Day 0, Day 1, Day 2, Day 30, Day 90
+9 more outcomes measured

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT04947657

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • East Jefferson General Hospital

    New Orleans, Louisianastudy coordinator listed

    Recruiting

  • Tulane Doctors - Speciality Care - Napoleon

    New Orleans, Louisianastudy coordinator listed

    Recruiting

  • University Medical Center

    New Orleans, Louisianastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amitabh Pandey, MD · PRINCIPAL_INVESTIGATOR · Tulane University

Who to contact

Mayana Bsoul, MD
[email protected]
504-988-3063
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients, male or female and older than 18 years of age.
Patients diagnosed with persistent or paroxysmal AF.
Patients that are undergoing catheter ablation at Tulane University Medical Center.
Patients that had a cardiac MRI prescribed by their physician as part of their standard of care.

Exclusion

Patients with coagulation disorders such as, von Willebrand disease, hemophilia, Immune Thrombocytopenic Purpura, etc.
Patients who are pregnant or breast-feeding or plan to become pregnant during the study period.
Are not surgically sterile.
Are of childbearing potential and are unwilling to practice two acceptable methods of birth control.
Do not plan to continue practicing two acceptable methods of birth control throughout the trial (highly effective methods of birth control are defined as those, used alone or in combination, that result in a low failure rate i.e. less than 1% per year when used consistently and correctly).
Patients with mental and/or physical ailments which may prohibit them from actively participating in the study.
Any health-related gadolinium/MRI contraindications (e.g. allergy to gadolinium, pacemakers, Implantable Cardioverter Defibrillators (ICD's), other devices/implants contraindicated for use of MRI, etc.)
Patients who have a known terminal illness with a prognosis less than 12 months at the time of the informed consent process.
Planned cardiovascular intervention.
Patient with diagnosed acute or chronic severe kidney disease or with a low glomerular filtration rate (GFR), \<30 mL per minute per 1.73 m2
Patients who cannot read, speak, and/or understand English.
Patients with cognitive impairments who are unable to give informed consent.

What this trial measures

  • Measure the change in Asymmetric dimethyl arginine (ADMA) in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between ADMA and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. ADMA will be measured in ng/mL.

  • Measure the change in markers of platelet activation P-selectin and Platelet factor 4 in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between the markers of platelet activation P-selectin and Platelet factor 4 and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. P-selectin and Platelet factor 4 will be measured in ng/mL.

  • Measure the change in B-thromboglobulin in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between B-thromboglobulin and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. B-thromboglobulin will be measured in µg/L.

  • Measure the change in coagulation marker Von Willebrand factor in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between coagulation marker Von Willebrand factor and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. Von Willebrand factor will be measured in IU/dL.

  • Measure the change in Thrombin Antithrombin levels in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between Thrombin Antithrombin levels and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. Thrombin Antithrombin levels will be measured in ng/ml.

  • Measure the change in Prothrombin time (PT) in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between Prothrombin time and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. PT will be measured in seconds.

  • Measure the change in Fibrinogen levels in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between Fibrinogen levels and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. Fibrinogen levels will be measured in mg/dL.

  • Measure the change in Factor 8 in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between Factor 8 and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. Factor 8 will be measured in Percent.

  • Measure the change in Factor 11 in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between Factor 11 and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. Factor 11 will be measured in U/dL.

  • Measure the change in D-dimers in relation to atrial fibrillation burdenDay 0, Day 1, Day 2, Day 30, Day 90

    Blood samples will be collected from patients at different time points to measure the correlation between D-dimers and the atrial fibrillation burden. One sample will be collected before the cardiac ablation at day 0, 2 samples will be collected during ablation at day 1, one sample at day 2, 1 sample at day 30, and one sample at day 90. Atrial fibrillation burden will be obtained from the patients charts review. D-dimers will be measured in ng/mL.